What's next for Boston Scientific after Farapulse's FDA approval?

Chief Medical Officer Dr. Ken Stein explains the plans at Boston Scientific after its landmark pulsed field ablation approval

Related Keywords

Boston , Massachusetts , United States , Ken Stein , Mike Mahoney , Nick Spadea Anello , Boston Scientific , Medtronic , Chief Medical Officer , September Investor Day , Versacross Connect , September Investor ,